These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 20445328)

  • 21. Chronic myelocytic leukemia with marked myelofibrosis and osteosclerosis.
    Honma K; Nemoto K; Ohnishi Y
    Acta Pathol Jpn; 1983 May; 33(3):599-607. PubMed ID: 6578670
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Essential thrombocythemia that transformed to myelofibrosis after three years].
    Akimoto Y; Ishiyama T; Sano M; Ueno H; Nakamaki T; Hino K; Tomoyasu S; Tsuruoka N
    Rinsho Ketsueki; 1992 Apr; 33(4):520-4. PubMed ID: 1602618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a role for the use of IFN-α in primary myelofibrosis?
    Nguyen HM; Kiladjian JJ
    Hematology Am Soc Hematol Educ Program; 2012; 2012():567-70. PubMed ID: 23233636
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blood tests may predict early primary myelofibrosis in patients presenting with essential thrombocythemia.
    Carobbio A; Finazzi G; Thiele J; Kvasnicka HM; Passamonti F; Rumi E; Ruggeri M; Rodeghiero F; Luigia Randi M; Bertozzi I; Vannucchi AM; Antonioli E; Gisslinger H; Buxhofer-Ausch V; Gangat N; Rambaldi A; Tefferi A; Barbui T
    Am J Hematol; 2012 Feb; 87(2):203-4. PubMed ID: 22237692
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombospondin-1 (TSP-1) in primary myelofibrosis (PMF) - a megakaryocyte-derived biomarker which largely discriminates PMF from essential thrombocythemia.
    Muth M; Engelhardt BM; Kröger N; Hussein K; Schlué J; Büsche G; Kreipe HH; Bock O
    Ann Hematol; 2011 Jan; 90(1):33-40. PubMed ID: 20625903
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Case of intraspinal epidural tumor developing after systemic mastocytosis with marked osteosclerosis and myelofibrosis].
    Ohnishi K; Torimoto Y; Itabashi K; Inamura J; Shindo M; Ikuta K; Sato K; Kohgo Y
    Rinsho Ketsueki; 2005 Oct; 46(10):1146-51. PubMed ID: 16440779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. AJR teaching file: Diffuse osteosclerosis with hepatosplenomegaly.
    Cloran F; Banks KP
    AJR Am J Roentgenol; 2007 Mar; 188(3 Suppl):S18-20. PubMed ID: 17312082
    [No Abstract]   [Full Text] [Related]  

  • 28. Histological and molecular classification of chronic myeloproliferative disorders in the age of JAK2: persistence of old questions despite new answers.
    Hussein K; Bock O; Kreipe H
    Pathobiology; 2007; 74(2):72-80. PubMed ID: 17587878
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bone marrow biopsy (BMB). II. Bone marrow biopsy in myeloproliferative disorders.
    Macavei I; Galatâr N
    Morphol Embryol (Bucur); 1989; 35(2):117-27. PubMed ID: 2529429
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of Endothelin-1 in a Syndrome of Myelofibrosis and Osteosclerosis.
    Yachoui R; Kristianto J; Sitwala K; Blank RD
    J Clin Endocrinol Metab; 2015 Nov; 100(11):3971-4. PubMed ID: 26358171
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bone marrow histomorphology and JAK2 mutation status in essential thrombocythemia.
    Stauffer Larsen T; Hasselbalch HC; Pallisgaard N; Møller MB
    APMIS; 2007 Nov; 115(11):1267-73. PubMed ID: 18092959
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival and disease progression in essential thrombocythemia are significantly influenced by accurate morphologic diagnosis: an international study.
    Barbui T; Thiele J; Passamonti F; Rumi E; Boveri E; Ruggeri M; Rodeghiero F; d'Amore ES; Randi ML; Bertozzi I; Marino F; Vannucchi AM; Antonioli E; Carrai V; Gisslinger H; Buxhofer-Ausch V; Müllauer L; Carobbio A; Gianatti A; Gangat N; Hanson CA; Tefferi A
    J Clin Oncol; 2011 Aug; 29(23):3179-84. PubMed ID: 21747083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria.
    Gisslinger H; Jeryczynski G; Gisslinger B; Wölfler A; Burgstaller S; Buxhofer-Ausch V; Schalling M; Krauth MT; Schiefer AI; Kornauth C; Simonitsch-Klupp I; Beham-Schmid C; Müllauer L; Thiele J
    Leukemia; 2016 May; 30(5):1126-32. PubMed ID: 26710883
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Follow-up examinations including sequential bone marrow biopsies in essential thrombocythemia (ET): a retrospective clinicopathological study of 120 patients.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Zankovich R; Diehl V
    Am J Hematol; 2002 Aug; 70(4):283-91. PubMed ID: 12210809
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
    Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
    J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Atypical myeloproliferative neoplasm with a small population of Philadelphia chromosome-positive clones in the bone marrow].
    Takai K; Ushiki T; Nikkuni K; Hashidate H; Shibuya H
    Rinsho Ketsueki; 2011 Feb; 52(2):73-7. PubMed ID: 21403427
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Essential thrombocythemia vs. early/prefibrotic myelofibrosis: why does it matter.
    Barosi G
    Best Pract Res Clin Haematol; 2014 Jun; 27(2):129-40. PubMed ID: 25189724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Diagnosis of osteomyelofibrosclerosis].
    Rückle H; Waller HD
    Dtsch Med Wochenschr; 1978 Jan; 103(4):142-3. PubMed ID: 624256
    [No Abstract]   [Full Text] [Related]  

  • 39. Prognostic significance of a comprehensive histological evaluation of reticulin fibrosis, collagen deposition and osteosclerosis in primary myelofibrosis patients.
    Gianelli U; Fiori S; Cattaneo D; Bossi A; Cortinovis I; Bonometti A; Ercoli G; Bucelli C; Orofino N; Bulfamante G; Iurlo A
    Histopathology; 2017 Dec; 71(6):897-908. PubMed ID: 28710830
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Frequent detection of the JAK2 V617F mutation in bone marrow core biopsy specimens from chronic myeloproliferative disorders using the TaqMan polymerase chain reaction single nucleotide polymorphism genotyping assay: a retrospective study with pathologic correlations.
    Bousquet M; Le Guellec S; Quelen C; Rigal-Huguet F; Delsol G; Brousset P
    Hum Pathol; 2006 Nov; 37(11):1458-64. PubMed ID: 16949922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.